Phase 2b study to evaluate the rate of onset of action of RDX227675 along with safety and efficacy in patients with chronic kidney disease (CKD) with or without heart failure (HF)
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2017
At a glance
- Drugs RDX 7675 (Primary)
- Indications Hyperkalaemia; Kidney disorders
- Focus Therapeutic Use
- 03 Jan 2017 Status changed from planning to recruiting, as per an Ardelyx media release.
- 28 Jun 2016 New trial record
- 22 Jun 2016 According to Ardelyx media release, this study is in accordance with FDA's request to evaluate onset of action of RDX227675.